Preliminary evaluation in vitro of the inhibition of cell proliferation, cytotoxicity and induction of apoptosis by 1,4-bis(1-naphthyl)-2,3-dinitro-1,3-butadiene Maurizio VialeMaria A. MariggiòMarino Novi OriginalPaper Pages: 359 - 367
Antineoplastic potency of arylchloroethylurea derivatives in murine colon carcinoma Elisabeth Miot-NoiraultJean LegaultJean Claude Madelmont OriginalPaper Pages: 369 - 378
Growth inhibition, G1-arrest, and apoptosis in MCF-7 human breast cancer cells by novel highly lipophilic 5-fluorouracil derivatives Juan Antonio MarchalHouria BoulaizAntonia Aránega OriginalPaper Pages: 379 - 389
Inhibitory effect of polypeptide from Chlamys farreri on UVA-induced apoptosis in human keratinocytes Mei DouYanTao HanYingYi Hou OriginalPaper Pages: 391 - 398
Antiproliferative effects of ZD0473 (AMD473) in combination with 5-Fluorouracil or SN38 in human colorectal cancer cell lines Carmen PlasenciaAlbert AbadMiquel Taron OriginalPaper Pages: 399 - 409
Antitumor efficacy and acute toxicity of the novel dipeptide melphalanyl-p-L-fluorophenylalanine ethyl ester (J1) in vivo Joachim GullboElin LindhagenRolf Larsson OriginalPaper Pages: 411 - 420
Phase I trial of continuous infusion recombinant human interleukin-4 in patients with cancer Navneet S. MajhailMohamad HusseinRonald M. Bukowski OriginalPaper Pages: 421 - 426
Phase I/pharmacokinetic study of CCI-779 in patients with recurrent malignant glioma on enzyme-inducing antiepileptic drugs Susan M. ChangJohn KuhnMichael D. Prados OriginalPaper Pages: 427 - 435
A phase I and pharmacokinetic study of the nonpolyglutamatable thymidylate synthase inhibitor ZD9331 plus docetaxel in patients with advanced solid malignancies Garry H. SchwartzChristopher B. JonesEric K. Rowinsky OriginalPaper Pages: 437 - 448
Phase I clinical trial of CEP-2563 dihydrochloride, a receptor tyrosine kinase inhibitor, in patients with refractory solid tumors Samir D. UndeviaNicholas J. VogelzangMark J. Ratain OriginalPaper Pages: 449 - 458
A phase I surrogate endpoint study of SU6668 in patients with solid tumors Henry Q. XiongRoy HerbstJames L. Abbruzzese OriginalPaper Pages: 459 - 466
A phase II pilot study of high-dose 24-hour continuous infusion of 5-FU and leucovorin and low-dose PALA for patients with colorectal cancer: A Southwest Oncology Group study Robert P. WhiteheadJacqueline K. BenedettiJohn S. Macdonald OriginalPaper Pages: 467 - 473
Gemcitabine and cisplatin chemotherapy is an active combination in the treatment of platinum-resistant ovarian and peritoneal carcinoma Devansu TewariBradley J. MonkRobert A. Burger OriginalPaper Pages: 475 - 480
Docetaxel plus fractionated cisplatin is a safe and active schedule as first-line treatment of patients with advanced non-small cell lung cancer: Results of a phase II study José Luis FirvidaMargarita AmenedoGustavo Losada OriginalPaper Pages: 481 - 487